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Abstract
Background: Understanding HIV-1 subtype distribution and epidemiology can assist preventive measures and
clinical decisions. Sequence variation may affect antiviral drug resistance development, disease progression,
evolutionary rates and transmission routes.
Results: We investigated the subtype distribution of HIV-1 in Europe and Israel in a representative sample of
patients diagnosed between 2002 and 2005 and related it to the demographic data available. 2793 PRO-RT
sequences were subtyped either with the REGA Subtyping tool or by a manual procedure that included
phylogenetic tree and recombination analysis. The most prevalent subtypes/CRFs in our dataset were subtype B
(66.1%), followed by sub-subtype A1 (6.9%), subtype C (6.8%) and CRF02_AG (4.7%). Substantial differences in the
proportion of new diagnoses with distinct subtypes were found between European countries: the lowest
proportion of subtype B was found in Israel (27.9%) and Portugal (39.2%), while the highest was observed in Poland
(96.2%) and Slovenia (93.6%). Other subtypes were significantly more diagnosed in immigrant populations. Subtype
B was significantly more diagnosed in men than in women and in MSM > IDUs > heterosexuals. Furthermore, the
subtype distribution according to continent of origin of the patients suggests they acquired their infection there or
in Europe from compatriots.
Conclusions: The association of subtype with demographic parameters suggests highly compartmentalized
epidemics, determined by social and behavioural characteristics of the patients.
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Background
Human immunodeficiency virus type 1 (HIV-1) is char-
acterized by extensive genetic diversity. HIV-1 strains
are divided in four groups (M, N, O and P), originating
from four separate cross-species transmissions from
chimpanzees and/or gorillas to humans. While HIV-1
groups O, N and P are mainly restricted to Central
Africa, group M has caused the HIV pandemic [1-4].
HIV-1 group M has been further classified into 9
distinct subtypes, sub-subtypes and inter-subtype circu-
lating recombinant forms (CRFs). Subtypes and sub-
subtypes arose from founder effects at different time
points in the past, and inter-subtype recombinants can
arise in patients co-infected with strains from two differ-
ent subtypes. If these newly recombined strains have a
significant epidemic spread, they are called Circulating
Recombinant Forms (CRFs) [5].
The spread of HIV-1 subtypes is important for epi-
demiological purposes but can also be of relevance in
clinical settings. Some biological properties differ be-
tween subtypes. They have different rates of evolution
and their sequence variation may affect antiviral drug re-
sistance development [6-12], but overall limited differ-
ences are found in the genetic barrier to drug resistance
development between subtypes [13]. Other studies sug-
gested differences in disease progression: subtype D
seems to have a faster disease progression than subtypes
A or C [14,15]. In the absence of antiretroviral prophy-
laxis, subtype C is transmitted from mother-to-child
more frequently compared to subtype D, which in turn
is more frequently transmitted than subtype A [16,17].
Some studies suggest that sexual transmission of subtype
C is also more likely than of subtypes A and D [18,19].
In addition, it is still not well understood how to cope
with the genetic variability of HIV-1 for the development
of an efficient HIV-1 vaccine [20-22].
Hemelaar et al. documented the molecular epidemi-
ology of HIV-1 in the world in 2011 using convenience
sampling and a literature review. Subtype C was
described as the most prevalent globally, representing
48% of the infections, while subtypes A, B, CRF02_AG,
CRF01_AE, subtype G and D accounted for 12, 11, 8, 5,
5 and 2% of the infections, respectively. In this study,
subtype B accounted for 85% of HIV-1 infections in
Western and Central Europe, while subtype A, C and G
followed, with 2-3% of infections [23]. Another manu-
script by the EuroSIDA study group also based on ana-
lysis of HIV-1 genomic sequences from 939 HIV-1
patients from Europe, Israel and Argentina followed
from May 1994 onwards, documented a subtype B
prevalence of 86%, 2% of subtype A, 4% of subtype C
and 7% of other subtypes [24].
We had access to sequences from the SPREAD (Strategy
to Control Spread of HIV Drug Resistance) surveillance
programme, which is coordinated by the European Society
for Antiviral Resistance (ESAR). This programme was
initiated with the objective of reliably determining the
prevalence of transmission of drug resistance within the dif-
ferent patient risk-groups and to identify risk factors enhan-
cing the risk of transmission of drug resistance. A second
objective was to characterize the epidemiological and se-
quence diversity of HIV-1 in Europe. Different than in pre-
vious approaches, in this study the samples were collected
in a representative way from newly diagnosed patients
(http://www.esar-society.eu/). In this paper, we describe the
subtype distribution of HIV-1 in Europe and Israel, based
on the SPREAD sequences of three collection periods from
patients newly diagnosed between 2002 and 2005 [25,26].
Results
Subtype B accounts for 70% of HIV-1 infections in newly
diagnosed patients living in Europe
Of the 2730 sequences included in the study, 2469 (90.4%)
were successfully subtyped using the REGA Subtyping
Tool version 2, while 261 (9.6%) were unclassified, of
which 137 sequences (5.0%) remained untypable even after
manual analysis. The subtypes with the highest proportion
of new diagnoses were subtype B - 66.12% [64.3-67.9%],
sub-subtype A1 - 6.9 [6.0-7.9%], subtype C - 6.8% [5.9-
7.8%] and subtype G - 3.8% [3.1-4.6%]. Among the recom-
binants, the most common CRFs were: CRF02_AG – 4.7%
[4.0-5.6%] and CRF01_AE – 4.0% [3.3-4.8%]. The propor-
tion of U/URFs in this dataset was 5.0% [4.2-5.9%]
(Table 1). When adjusting for oversampling in some coun-
tries (Additional file 1: Figure S1), the proportion of new
diagnoses with subtype B increased to 70.2%; subtypes C
and A decreased to 5.0 and 3.6% respectively; CRF02_AG
and subtype G increased to 4.9% and 4.8% respectively;
CRF01_AE decreased to 1.9%; and U/URFs increased to
5.8% (Additional file 2: Figure S2). Even though some of
these differences are statistically significant, they are lim-
ited to the extent that they have no substantial impact on
the remaining analyses, and are thus not further reported
separately. All adjusted analyses can be found in supple-
mentary materials.
HIV-1 molecular epidemiology is highly heterogeneous
between European countries
The country of sampling corresponds to the country
where the sample and questionnaire were collected. For
most cases the “country of sampling” corresponds also
to the area where the patient resides and is clinically fol-
lowed. For all countries, the subtype with the highest
proportion of new diagnoses was subtype B, except
Israel, where subtype C was more prevalent than subtype
B (58.1 vs 27.9%). The countries with the highest propor-
tion of non-B subtypes were Israel and Portugal (72.1 %
and 60.8%, respectively). This is due to the parallel
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epidemics of subtypes B and C and subtypes B and G in
Israel and Portugal, respectively. Poland and Slovenia were
on the opposite side, with the lowest proportion of non-B
subtypes (5.0% and 6.5%) (Figure 1; Additional file 3:
Figure S3 and Additional file 4: Table S1).
New diagnoses with subtype B occurred in 79% of
patients originating from and living in Europe
The country of origin corresponds to the country where
the patient was born. When re-analyzing the distribution
of subtypes including only patients who originated from
SPREAD countries (n = 2225), the proportion of newly
diagnosed patients infected with subtype B increased sig-
nificantly from 66.1% to 79.5%. Subtypes or CRFs A1,
CRF01_AE, CRF02_AG and C decreased significantly
from 6.9%, 4.0%, 4.7% and 6.8% to 5.2%, 2.6%, 1.7% and
2.5% respectively, while the proportion of subtype G
remained approximately stable (3.8% to 3.3%) (Table 1).
A significant rise in proportion of newly diagnosed in
this analysis means that the respective subtype is less
found among the immigrant population.
The proportion of new diagnoses with different subtypes
among native populations is country-specific
Table 2 shows per country the 1st, 2nd and 3rd most
prevalent subtypes sampled, as well as the 1st, 2nd and
3rd more prevalent subtypes among the native popula-
tion. No consistent pattern exists for the proportion of
new diagnoses with non-B subtypes among natives. In
Belgium, the second most prevalent subtype was
CRF02_AG in patients sampled in Belgium, while sub-
type C was more prevalent in patients originating from
Belgium, implying that the high proportion of
CRF02_AG is mostly caused by immigrants (in this case
originating from Africa), while subtype C seems to have
established among the Belgian population, alongside
subtype B. In Portugal, subtype G is well established in
the native population, while in Greece and Cyprus sub-
type A1 is well established in natives.
The most extreme case of discrepancy in infecting
subtypes between natives and immigrants is Israel,
where natives are exclusively infected with subtype B
and the majority of infected immigrants - mainly from
Ethiopia – are infected with subtype C.
The HIV-1 subtypes infecting immigrant patients living in
Europe are mostly similar to the HIV-1 subtypes causing
epidemics in their country/continent of origin
When analyzing the distribution of subtypes of the
patients originating from countries other than SPREAD
countries, we found results consistent with our current
HIV-1 molecular epidemiological knowledge in those
countries, suggesting that the country where the patient
originates is also the country where the infection was
acquired or that they acquired their infection in Europe
from compatriots (Additional file 5: Figure S4; Additional
file 4: Table S2). The logistic regression results were con-
sistent with these results by indicating continent of origin
and countries of origin as significantly associated with the
proportion of new diagnoses with different subtypes (see
Additional file 4: Table S3 for details) while country of
sampling was rarely associated with it.
The distribution of subtypes according to the contin-
ent of origin of the patient is represented in Figure 2.
The proportion of newly diagnosed with subtype B was
higher in patients from Western Europe (76.59%), Latin
America (78.18%) and Eastern Europe and Central Asia
(86.59%). In patients from South and South-East Asia,
the most prevalent subtype was CRF01_AE (63.93%). Fi-
nally, in patients from Sub-Saharan Africa, almost all
subtypes were found, but subtype C seems to dominate
the epidemic (31.21%). Albeit subtype B was the most
prevalent subtype in patients originating from North
Africa and Middle East (58.33%), subtype C was also
very prevalent in these patients (16.67%), (Figure 2).
HIV-1 molecular epidemiology in Europe is highly
stratified according to gender and risk group
The distribution of different subtypes according to gen-
der is represented in Figure 3. The proportion of subtype
Table 1 Percent subtypes for the complete set of patients
and only for patients originating from SPREAD countries
and 95% confidence intervals
All
patients
95% C.I. Patients
originating
from
SPREAD
countries
95% C.I. p-value
A1 6.92 [6.00-7.94] 5.24 [4.30-6.32] p=0.012
B 66.12 [64.31-67.90] 79.48 [77.63-81.25] p<2.2x10-06
C 6.78 [5.86-7.79] 2.55 [1.90-3.34] 2.4x10-11
D 0.81 [0.51-1.22] 0.15 [0.03-0.45] N.S.
F 1.28 [0.89-1.78] 1.12 [0.70-1.69] N.S.
G 3.81 [3.12-4.60] 3.31 [2.56-4.20] N.S.
AE 3.95 [3.26-.76] 2.60 [1.94-3.40] p=0.009
AG 4.73 [3.96-5.59] 1.73 [1.20-2.411] p=2.1x10-08
Others 0.59 [0.34-0.95] 0.20 [0.06-0.52] N.S.
U/URFs 5.02 [4.23-5.91] 3.62 [2.83-4.54] N.S.
P-values are for comparisons between the complete dataset and for the
dataset including only patients originating from SPREAD countries.
AE – CRF01_AE.
AG – CRF02_AG.
Others – Samples classified as other subtypes or CRFs.
A1 – Sub-subtype A1.
B – Subtype B.
C – Subtype C.
D – Subtype D.
F – Subtype F.
G – Subtype G.
U/URFs – Samples classified as Untypable (U), partially Untypable or as Unique
Recombinant Forms (URFs).
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B is significantly higher in men than in women, while
the proportion of subtypes A1, C, G, CRF01_AE,
CRF02_AG and U/URFs is significantly higher in
women.
The proportion of subtype B is significantly higher in
MSM (men who have sex with men) patients than in
IDUs and in heterosexuals and is significantly higher in
IDUs than in heterosexual patients. Subtype A1 was sig-
nificantly more prevalent in heterosexuals (9.48%) than
in MSM (4.9%), but it was the 2nd most prevalent sub-
type in MSM, with all other subtypes less than 1.3%.
These patients were mostly from Greece (n=53), but also
from Cyprus (n=3), Portugal (n=2), Spain (n=1), the
Netherlands (n=1) and Ireland (n=1). The increase
in proportion of subtypes A1 and C has also been
described in the MSM population of the United
Kingdom [27]. Subtype G was significantly less prevalent
in MSM (0.32%) than in IDUs (10.05%) and heterosexuals
(7.20%), while subtypes C, CRF02_AG and CRF01_AE
were significantly more prevalent in heterosexuals (15.7%,
7.41% and 9.16% respectively) than in IDUs (1.44%, 3.35%
and 0.48% respectively) and MSM(0.48%, 1.04% and 1.28%
respectively). URFs were found significantly more in het-
erosexuals than in MSM (Figure 4).
Logistic regression indicated risk group MSM as
a positive predictor of infection by subtype B, while
heterosexual risk group is linked to infection with sub-
subtype A1 and subtype C. Risk group MSM also indi-
cates lower risk of infection with CRF01_AE, CRF02_AG
and subtypes C and F. See Additional file 4: Table S3 for
Odds Ratios.
Continent and country of origin and risk factor are the
main determinants of subtype distribution
Multinomial logistic regression indicated that gender,
risk group and continent of origin were the main
Figure 1 Proportion of diagnoses with subtype B by country of sampling of the patient. AT – Austria (n=99), BE – Belgium (n=220),
CY – Cyprus (n=24), DK – Denmark (148), FI – Finland (n=48), DE – Germany (n=364), GR – Greece (251), IE – Ireland (n=38), IT – Italy (199),
LU – Luxembourg (n=35), NL – Netherlands (n=97), NO – Norway (n=94), PL – Poland (n=121), PT – Portugal (n=240), SI – Slovenia (n=62),
ES – Spain (n=206), SE – Sweden (n=210), CS – Serbia (n=67), CZ – Czech Republic (n=143), SK – Slovakia (n=11), IL – Israel (n=43).
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Table 2 Proportion of new diagnoses with the 1st, 2nd and 3rd most observed subtypes in each country of sampling
compared to 1st, 2nd and 3rd most observed subtypes among natives (unadjusted values only)
1st %* 2nd % 3rd %
AT samp B 50.50 CRF01_AE 13.13 AG 12.12
AT origin B 61.76 CRF01_AE 16.18 A1 11.76
BE samp B 53.18 CRF02_AG 10.45 C 8.18
BE origin B 81.36* C 5.93 CRF02_AG 2.54
CY samp B 45.83 A1 37.50 C 8.33
CY origin B 73.68 A1 21.05 C 5.26
CZ samp B 76.92 A1 9.09 CRF01_AE 6.99
CZ origin B 90.18* A1 3.57 C 2.68
DE samp B 89.84 CRF02_AG 3.30 CRF01_AE 2.20
DE origin B 95.86* CRF01_AE 1.59 CRF02_AG 0.96
DK samp B 60.14 C 10.81 CRF01_AE and A1 7.43
DK origin B 79.17* AE and G 5.21 C 4.17
ES samp B 91.26 CRF02_AG 1.94 G 0.97
ES origin B 94.23 A1, C, F, G, AE, AG 0.64 - -
FI samp B 56.90 CRF01_AE 18.97 C 10.34
FI origin B 59.65 CRF01_AE 19.30 C 10.53
GR samp B 47.81 A1 29.88 C 5.98
GR origin B 51.67 A1 33.01 C 3.34
IE samp B 63.16 C 21.05 CRF02_AG 7.89
IE origin B 91.30* C 8.70 - -
IL samp C 58.14 B 27.91 A1 11.63
IL origin B 100.00 - - - -
IT samp B 75.88 F 8.54 CRF02_AG 6.03
IT origin B 85.43* F 9.93 AG and A1 1.32
LU samp B 68.57 C 11.43 G and U/URFs 8.57
LU origin B 90.00 - - - -
NL samp B 67.01 CRF02_AG and C 9.28 A1 7.22
NL origin B 88.00* C and AG 4.00 - -
NO samp B 52.13 C 19.15 CRF01_AE 6.38
NO origin B 86.27* C 7.84 CRF02_AG 1.96
PL samp B 95.04 CRF01_AE and C and F 0.83 - -
PL origin B 93.80 CRF01_AE, A1, C and F 0.77 - -
PT samp B 39.17 G 30.00 C 6.25
PT origin B 47.75 G 30.33 CRF02_AG 2.81
SE samp B 47.62 CRF01_AE and C 14.28 CRF02_AG 8.10
SE origin B 73.47* CRF01_AE 12.24 CRF02_AG 5.10
SI samp B 93.55 CRF01_AE and CRF02_AG and A1 1.61 - -
SI origin B 96.61 CRF02_AG 1.69 - -
SK samp B 81.82 C 9.09 - -
SK origin B 87.50 C 6.25 - -
CS samp B 88.06 G 5.97 CRF01_AE and C 2.99
CS origin B 88.20 G 5.88 CRF01_AE 2.38
* indicates that the difference between these two is significant. U/URFs were excluded from this table, since they represent a heterogeneous group of strains.
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determinants of subtype distribution. Country of sam-
pling was also indicated as a determinant of subtype
distribution by the regression model, but the p-value
(p>0.05) for this association was not significant
(Additional file 4: Table S4).
Logistic regression, however, is not the best method to
determine dependency between the variables. For that,
we used Bayesian Network analysis. Its use helps to de-
termine which associations occur directly between the
analysed variables and which associations are secondary
to other direct primary associations. In our Bayesian net-
work analysis, risk factor, continent of origin and coun-
try of origin were identified as unconditionally
associated with the infecting subtype, as illustrated by a
direct arc (Figure 5). However, only the arc connecting
continent of origin and HIV clade was confirmed by a
high bootstrap support (74% of the replicates). On the
other hand, countries of sampling and gender were
found to be only secondarily associated with subtype,
since there is no direct arc with subtype, rather the
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Figure 2 Subtype distribution stratified by continent of origin of the patient. Regional distribution of the countries was defined as in the
UNAIDS reports (Hemelaar, et al., 2006): Sub-Saharan Africa (S-S A, n=330), East Asia (n=2), Oceania (n=1), South and South-East Asia (S/S-E A,
n=61), Eastern Europe and Central Asia (EE/CA, n=425), Western Europe (WE, n=1636), North Africa and Middle East (NA/ME, n=36), North America
(n=7), Caribbean (n=11), Latin America (LA, n=55). Due to the low sample size, East Asia and Pacific, Oceania, North America and Caribbean are
not included in the figure. See Additional file 5: Table S5 for list of countries included in each continent region.
Figure 3 Subtype distribution by gender. A total of 307 females (blue bars) and 989 males (red bars) were included in the analysis. For 4
patients, this information was not available; and these were deleted from the data set. Asterisks indicate statistically significant differences in the
proportion of a certain subtype in male vs. female (p<0.05).
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connection is through the risk factor, continent of origin
and country of origin variables. For example, the arc that
connects continent of origin to HIV clade indicates that
there is a direct and unconditional dependence between
these two variables; therefore, the continent of origin of
the patient is an important determinant of the HIV clade.
On the other hand, gender is connected to HIV clade
through the risk group, which means that the unequal dis-
tribution of subtypes according to gender can be explained
by the fact that there is a difference in subtype epidemic
among MSM (all men) compared to heterosexual or IDU
(men and women). Similar extrapolations can be made to
other variables of the network (Figure 5).
The proportion of newly diagnosed with CRF02_AG and
subtype F increased significantly between 2002 and 2005
When analysing the proportion of diagnoses with differ-
ent HIV-1 subtypes stratified over the years according to
date of first positive confirmatory HIV-1 test, we found
that most subtypes did not show any significant trend.
The exception to this rule was CRF02_AG and subtype
F with a significantly increasing (p-value=0.05 and 0.03,
respectively) and subtype C with a significantly decreas-
ing trend between 2002 and 2005 (p=0.004). No signifi-
cant trends were found in the proportion of diagnoses
with subtype B, which increased in 2004 but then
decreased in 2005 (Figure 6).
Discussion
In this paper, we have described the HIV-1 subtype dis-
tribution and its associated socio-demographic factors in
newly diagnosed patients in West-Central Europe using
sequences from the SPREAD programme (http://www.
esar-society.eu/). Samples were collected between 2002
and 2005 from drug-naïve patients diagnosed not earlier
than 6 months before sampling, together with clinical
and epidemiological information. The sampling strategy
was based on representative sampling over countries and
risk groups, allowing a more accurate picture than in
previous studies that were either based on convenience
sampling [23] or focused solely on one country [28,29].
In addition, our study is unique since it permitted
to combine for the first time molecular data of a
‘continent’-scaled sample, together with demographic
and behaviour information of the patients. The primary
objective of the SPREAD study was to measure the ex-
tent of transmission of drug-resistant HIV, and an add-
itional objective was to characterize the genetic diversity
of the epidemic in Europe. For this second objective, we
subtyped all samples from three inclusion rounds of the
SPREAD programme (Sept 2002-Dec 2005), and ana-
lyzed the geographical spread and the factors associated
with this subtype distribution. Although SPREAD sam-
pling strategy was carefully designed to avoid sampling
bias, we noticed that not all countries were sampled at
the same density. Given the differences found in the
sampling rate of newly diagnosed patients especially in
small countries, we performed a weighted analysis to ac-
count for such differences. Such a strategy has, however,
its own limits since diagnosis rates may differ among
risk groups [30] or the proportion of infected patients
that are undiagnosed may differ between countries.
Figure 4 Proportion of diagnoses with different HIV-1 subtypes in different risk groups. IDUs (green bars) – intravenous drug users
(n=221); Homo-bi (red bars) – homobisexuals (n=1271); Hetero (blue bars)– heterosexuals (n=994). Asterisks indicate significant differences in the
proportion of one subtype between at least two of the risk groups. For example, for URFs the significant difference was found only between
homosexuals and heterosexuals (p=1.2x10-5) while subtype B has a significantly different frequency in all risk groups. For more details, please
refer to the methods and results sections.
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Although we found some significant differences with the
weighted analysis, this difference was not substantial and
did not result in different conclusions.
Because of its high specificity, even though at the cost
of sensitivity [31,32], we only used the Rega subtyping
tool in our study, and complemented it with manual
analysis for unclassified sequences. Although our subtyp-
ing methodology was extremely meticulous, a limitation
of any study using only one genetic region is the fact
that no claims can be made with regard to the absence
of recombination breakpoints outside of the sequenced
genomic regions.
Similar as in the UNAIDS report for Western Europe
[33], we found subtype B to be the most prevalent sub-
type but lower than reported before: 66.1% compared to
the 85% reported by UNAIDS. In the subset of patients
not only diagnosed but also originating from Europe the
proportion of subtype B among newly diagnosed
patients was significantly higher (79.5%) resembling the
UNAIDS data. These differences are thus likely
explained by the very different sampling strategies be-
tween the studies: UNAIDS used country of origin of
the patient, while we used country of sampling; and
UNAIDS used a convenience sample of data collected
from patients diagnosed at any time and we used a rep-
resentative sample of newly diagnosed patients. Subtypes
A1 (6.9%), C (6.8%) and CRF02_AG (4.7%) are the other
most prevalent subtypes in patients diagnosed in Europe.
Again here the results are not entirely consistent with
the UNAIDS report, where the most prevalent non-B
subtypes in Western and Central Europe were
CRF02_AG (2000–2003: 2.94%; 2004–2007: 4.50%) and
subtype C (2000–2003: 2.9%; 2004–2007: 1.91%). As in
our study only newly diagnosed patients were included
in the sample, a major advantage of our sampling strat-
egy is that it maps the more recent past compared to
previous studies. Our findings may therefore be more
relevant for the epidemic in the near future.
The information collected allowed us to make a
detailed analysis of the relationship between the socio-
demographic and other epidemiological indicators of the
patient and the HIV subtype. Despite the increasing
spread of different non-B subtypes, the continent of ori-
gin and the risk group of the patient are still good pre-
dictors of the subtype. While for now, we are still able to
attribute the proportion of new diagnoses with many
non-B subtypes in Europe to certain demographic
groups; this might change in the future. For example,
subtype G has already a well-established epidemic in
Portugal even within natives and in both heterosexual
and IDU risk groups. From our results, it is clear that
some non-B subtypes are still being imported into Eur-
ope and remain largely limited to migrant populations,
such as CRF02_AG in Belgium; while some have
Country
Country
of origin
Continent
of origin
HIV CLADE
Risk
group
Gender
Weak association 
(bootstrap < 70%)
Strong association 
(bootstrap > 70%)
Direct association
Indirect association
Figure 5 Bayesian networks of the variables that were found to
be associated with the subtype of the HIV-1 strain in the
univariate analysis. The variables gender, risk group and continent of
origin were grouped as described previously. Black arcs indicate
variables directly associated with the Subtypes/CRFs variable. Grey arcs
indicate indirect association with Subtypes/CRFs. Dotted arcs indicate
associations with low bootstrap support (<70%), while full arcs indicate
associations confirmed by a high bootstrap support (>70%). Country of
sampling included 20 countries: Austria, Belgium, Cyprus, Denmark,
Finland, Germany, Greece, Ireland, Italy, Luxembourg, Netherlands,
Norway, Poland, Portugal, Slovenia, Spain, Sweden, Serbia, Czech
Republic, Slovakia and Israel. Country of origin included: Netherland
Antilles, Angola, Argentina, Austria, Belgium, Burkina Faso, Burundi,
Benin, Brasil, Democratic Republic of Congo, Congo, Switzerland, Cote
D’Ivoire, Chile, Cameroon, China, Colombia, Cuba, Cape Verde, Cyprus,
Czech Republic, Germany, Djibouti, Denmark, Dominican Republic,
Algeria, Equator, Estonia, Egypt, Eritrea, Spain, Ethiopia, Finland, France,
United Kingdom, Georgia, Ghana, Gambia, Guinea, Equatorial Guinea,
Greece, Guinea-Bissau, Croatia, Ireland, Israel, India, Iraq, Iran, Iceland,
Italy, Kenya, South Korea, Liberia, Luxembourg, Latvia, Libyan Arab
Jamahiriya, Morocco, Myanmar, Mauritania, Mexico, Malaysia,
Mozambique, Niger, Nigeria, Netherland, Norway, New Zealand, Oman,
Peru, Pakistan, Poland, Portugal, Romania, Russia, Rwanda, Sudan,
Sweden, Singapore, Slovenia, Slovakia, Sierra Leone, Senegal, Somalia,
Suriname, Sao Tome and Principe, Syrian Arab Republic, Togo, Thailand,
Tunisia, Tonga, Turkey, Tanzania, Ukraine, Uganda, USA, Uruguay,
Venezuela, Serbia, Zambia, Zimbabwe and South Africa. However, only
to keep the number of instances in the variable country of origin
similar to the number of instance in the variable country of sampling;
only instances of Austria, Belgium, Cameroon, CS (Serbia), Czech
Republic, Germany, Denmark, Spain, Ethiopia, Finland, Greece, Italy,
Nigeria, The Netherlands, Norway, Poland, Portugal, Sweden, Slovenia,
Thailand and Yugoslavia were left ungrouped; while all other instances
of country of origin with smaller sample size were group together.
Abecasis et al. Retrovirology 2013, 10:7 Page 8 of 13
http://www.retrovirology.com/content/10/1/7
established themselves in the native European popula-
tion, like subtype G in Portugal and subtype A1 in
Greece. Similar observations can be made for the risk
group analysis, where subtypes are clearly compartmen-
talized in different transmission groups. This suggests
highly stratified epidemics occurring in each country
and risk group. HIV infection is still determined by so-
cial, behavioural and demographic characteristics of the
patients, and we should thus target preventive measures
to specific populations.
The subtype B epidemic was firstly described in the
MSM population [34], but was found in IDUs soon
afterwards [35]. Interestingly, the prevalence of subtype
B is still higher in the MSM risk group. This could either
indicate a higher transmission potential of subtype B in
MSM, or could just be a reflection of the long-term es-
tablishment of subtype B infection in this risk group,
that may be more compartmentalized than IDUs. Even
though some reports are consistent with the hypothesis
of a biological difference between subtypes with regard
to transmission rates and routes [36,37], with respect to
our findings, more data are needed to exclude simple
epidemiological circumstances. In this study, we find
that heterosexuals are more frequently infected with
non-B subtypes, and this is reflected in the higher pro-
portion of women – and consequently probably children
- infected with such strains. Finally, we find that the
MSM risk group presents a recent rise of proportion of
sub-subtype A1 infections (4.9%), mostly caused by an
epidemic among Greek MSMs.
The proportion of new diagnoses with HIV-1
CRF02_AG and subtype F increased significantly be-
tween 2002 and 2005, while for subtype C we saw a sig-
nificant decrease. No other significant time trends were
found, indicating stable epidemics of most HIV-1
subtypes. However, given the short time period studied
and the fact that most of the patients have an unknown
date of infection, no firm conclusions should be made in
this respect.
Although different subtypes of HIV-1 represent differ-
ent epidemics, they have been dealt as a single epidemic
in UNAIDS and ECDC reports. Herein, we present the
social, behavioural and demographic determinants of
HIV-1 subtype distribution in Europe. Stratifying results
by subtypes allows a better understanding of changing
prevalence and mobility of the virus.
Methods
Sample collection
Sequences included in the study were from 20 European
countries - Austria (AT), Belgium (BE), Cyprus (CY),
Denmark (DK), Finland (FI), Germany (DE), Greece (GR),
Ireland (IE), Italy (IT), Luxembourg (LU), Netherlands
(NL), Norway (NO), Poland (PL), Portugal (PT), Slovenia
(SI), Spain (ES), Sweden (SE), Serbia (CS), Czech Republic
(CZ), Slovakia (SK) - and Israel (IL). Samples were col-
lected from HIV-1 infected individuals in whom infection
was newly diagnosed between September 2002-December
2005, no longer than 6 months before sampling. To guar-
antee representativeness in each country, individuals were
selected according to the national distribution of transmis-
sion risk groups and the geographical distribution of
patients with new diagnoses of HIV-1 infection. The strat-
egies used to achieve this were: in countries where more
than 80% of all newly diagnosed individuals were expected
to be covered by the participating centers, a random sam-
ple from all newly identified individuals was taken. In
other countries, stratified sampling weighted for the pro-
portion of newly diagnosed patients among different risk
groups and among different geographical areas was
Figure 6 Proportion of different HIV-1 subtypes stratified according to year of diagnosis. In 2002, samples were collected only during the
last 3 months, and therefore this year was excluded from the analysis. 909 samples were collected in 2003, 1107 in 2004 and 513 in 2005.
Significance for increasing or decreasing trends was tested with the Cohran-Armitage test. Significant trends are indicated in the figure with an
asterisk. p-values are described in the text.
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performed or a consecutive number of patients up to a
predefined number per geographic region were included.
All recruited patients were antiretroviral drug naive at the
time of sampling, and drug resistance genotyping was per-
formed in the national reference laboratories as described
before [25,26]. Details about the study design were
reported previously and can be found on the website
(http://www.esar-society.eu/) [25,26].
Although the sampling strategy was cautiously
designed in order to representatively include different
countries and risk groups, unavoidably some discrepan-
cies in sampling numbers occurred between countries,
especially to attain a representative sample in small
countries. To assess the impact of such oversampling in
some countries, the weighted proportion of newly diag-
nosed was calculated. The HIV infection rate per coun-
try (number of yearly newly diagnosed HIV-1 cases per
inhabitant) was obtained for each included country
(ECDC Report 2004, derived from infection rate per mil-
lion) [33], and we estimated which percentage of
infected patients was sampled in each country. Since the
collection period was 39 months, we adjusted the num-
ber of samples to a 12 months period. Mathematically,
the proportion of the HIV infected that was sampled
corresponds to:
% of infected
inhabitants
in country A
¼
Number of samples collected in country Að Þ12 months
Population size country Að Þ39 months
Rate per million 2004 of country A
1000000
Since the % of infected inhabitants sampled was vari-
able between countries, the counts of subtypes of each
country were weighted accordingly in the determination
of the proportion of newly diagnosed patients with dif-
ferent subtypes in Europe. Although there were some
significant differences, the overall conclusions of our
analysis did not change. Therefore, the unweighted pro-
portion is given, unless specified, and all weighted ana-
lyses can be found in supplementary material.
Subtyping
Automatic subtyping
Sequences were subtyped using the REGA Subtyping
tool version 2 (http://jose.med.kuleuven.ac.be/genotypetool/
html/subtypinghiv.html) [31,38]. Detailed information
about the algorithm of the REGA Subtyping tool version
2 are available on the website: http://www.bioafrica.net/
subtypetool/html/.
Reports generated by the subtyping tool were individu-
ally viewed and a csv formatted file with the results was
downloaded.
Manual subtyping
For sequences that were too complex for the REGA sub-
typing tool to assign it to a subtype or CRF automatically
and that were therefore classified as ‘Unassigned’, a man-
ual subtyping procedure was used. In this procedure, the
sampled sequences were aligned against reference
sequences of all pure subtypes and the reference
sequences of the first 14 CRFs, using the reference set as
described in the Los Alamos database. Although 51
CRFs have been described, CRFs 15 to 51 are not re-
sponsible for important epidemics and a BLAST search
indicated none were present among our data. Therefore,
we decided to leave them out from the phylogenetic ana-
lysis. The multiple alignment was generated using Clus-
talW [39] and manually edited with Se-Al v2.0 [40]. The
sequences were then tested for evidence of recombin-
ation using the bootscan plot as implemented in Simplot
v3.5.1. Phylogenetic analyses were performed with and
without including CRF reference sequences in the data-
sets. The putative recombination pattern was confirmed
by separate phylogenetic analysis in the fragments with
different evolutionary history. Any genomic region was
assigned to a certain HIV subtype if it clustered with
reference sequences of this subtype and this clustering
was supported by bootstrap values higher than 70%.
Statistical analysis
Potential associations between demographic and other
parameters (area of transmission, ethnicity, etc.) and the
distribution of B and non-B subtypes were statistically
analysed. The SPREAD questionnaire included informa-
tion about gender, age, risk factor, continent and country
of origin, country of sampling and country where infec-
tion was obtained. The univariate analysis of association
between these factors and proportion of B vs non-B, C
vs non-C, A1 vs non-A1, G vs non-G, CRF01_AE vs
non-CRF01AE, CRF02AG vs non-CRF02AG subtypes
and URFs vs non-URFs was tested using the Chi-square
test. The p-values of the chi-square test were calculated
using the R package [41]. The Holm-Bonferroni method
was used to check whether multiple testing could lead to
a false rejection of the null hypothesis (type I error). The
odds ratio (OR) and the 95% confidence interval (CI) of
the OR were calculated using a small script in Microsoft
Excel. A multivariate analysis was also done with step-
wise logistic regression, using as start variables: a) all
variables; b) only the variables that were statistically sig-
nificant in the previously described univariate analysis
(p≤ 0.05). Both binary and multinomial logistic regres-
sion were performed with the R package.
Bayesian networks (BN) were run for variables that were
significantly associated with the distribution of HIV-1 sub-
type/CRF using the univariate analysis. A BN is a probabil-
istic graphical model that illustrates the relationships
among a set of variables. These relationships – dependen-
cies - are defined by a set of nodes that represent the vari-
ables and a set of arcs that represent direct/unconditional
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dependencies between two variables in the dataset. The
lack of an arc between two variables represents a condi-
tional independency, meaning that these two variables are
only dependent through another variable [42]. This ana-
lysis allows to map the interdependence of the analysed
parameters unveiling direct and indirect associations with
the HIV-1 subtype/CRF. The best BN that models the
observed correlations is determined by a scoring metric
(trade-off between model complexity and accuracy), and
we use a Bayesian metric that considers the most probable
one as the best network (maximizing posterior probability
of the model given the data). Since an exact search is com-
putationally impossible, we use the search heuristic of
simulated annealing. We then use non-parametric boot-
strap resampling to assess how strongly the data support
the most probable network. A bootstrap analysis with 100
replicates was then used to investigate the reproducibility
of each arc of the BN. 70% bootstrap support was used as
the cut-off to assign reliable arcs. To remove the bias
caused by variable instances that are present in very few
patients (less than 1%), we combined those instances to-
gether in a single instance called ‘Others’. This procedure
was done using the preprocessing filter available in the
WEKA software.
Finally, to test for time trends in subtype distribution,
we used the Cochran-Armitage test as implemented in
the prop.trend.test function in the stats package of the R
package.
Additional files
Additional file 1: Figure S1. Percentage of samples of the dataset
sampled in each country (dark grey) (see methods for details on calculations
involved) and percentage of infected inhabitants that was sampled in each
country (white) as reported by the ECDC-UNAIDS in the 2004 report.
AT – Austria, BE – Belgium, CY – Cyprus, DK – Denmark, FI – Finland,
DE – Germany, GR – Greece, IE – Ireland, IT – Italy, LU – Luxembourg,
NL – Netherlands, NO – Norway, PL – Poland, PT – Portugal, SI – Slovenia,
ES – Spain, SE – Sweden, CS – Serbia, CZ – Czech Republic, SK – Slovakia,
IL – Israel.
Additional file 2: Figure S2. Prevalence of subtypes for the complete
dataset of patients not adjusted (left bars), for the complete dataset of
patients adjusted according to size of the sample with respect to the
epidemic (middle bars) and for the set of patients originating from
SPREAD countries (right bars). Legend presents percentage values and
95% confidence intervals for each bar. See methods for details on the
procedure to adjust for sampling bias. Asterisks indicate statistically
significant differences in the prevalence of a certain subtype (p<0.05)
when comparing the complete dataset and the dataset including only
patients originating from SPREAD countries.
Additional file 3: Figure S3. Subtypes distribution by country of
sampling of the patient. AT – Austria, BE – Belgium, CY - Cyprus,
DK – Denmark, FI – Finland, DE – Germany, GR – Greece, IE – Ireland,
IT – Italy, LU – Luxembourg, NL – Netherlands, NO – Norway,
PL – Poland, PT – Portugal, SI – Slovenia, ES – Spain, SE – Sweden,
CS – Serbia, CZ – Czech Republic, SK – Slovakia, IL – Israel.
Additional file 4: Table S1. – Subtypes distribution by country of
sampling of the patient. Table S2. – Subtypes distribution by country of
origin of the patient. AO – Angola, AT – Austria, BE – Belgium,
BI – Burundi, BR – Brazil, CG – Congo, CM – Cameroon, CS – Serbia,
CV – Cape Verde, CY – Cyprus, CZ – Czech Republic, DE – Germany,
DK – Denmark, ES – Spain, ET – Ethiopia, FI – Finland, GR – Greece,
IE – Ireland, IT – Italy, KE – Kenya, NG – Nigeria, NL – The Nederlands,
NO – Norway, PL – Poland, PT – Portugal, RU – Russian Federation,
SE – Sweden, SI – Slovenia, SK – Slovakia, TH – Thailand, UA – Ukraine,
YU – Yugoslavia. Table S3. – Goodness of fit for the logistic model, Odds
ratio with Confidence Interval and p-values for the association between
HIV-1 subtypes prevalence and demographic parameters. Associations
were calculated using binomial logistic regression (see methods for
details). Sub-Saharan Africa - SSA, South and South-East Asia –SS EA.
Eastern Europe and Central Asia - EE CA. Western Europe – WE.
Table S4. – Goodness of fit for the logistic model, Odds ratio with
Confidence Interval and p-values for the association between HIV-1
subtypes prevalence and demographic parameters. Associations were
calculated using multinomial logistic regression (see methods for details).
Table S5. – List of countries included in each continent region.
Additional file 5: Figure S4. Subtypes distribution by country of origin
of the patient. Left: DE – Germany, GR – Greece, PT – Portugal,
PL – Poland, ES – Spain, IT – Italy, BE – Belgium, CZ – Czech Republic,
DK – Denmark, SE – Sweden, AT – Austria, SI – Slovenia, FI – Finland,
NL – The Nederlands, NO – Norway. Right: ET – Ethiopia,
CM – Cameroon, YU – Yugoslavia, TH – Thailand, NG – Nigeria,
CS – Serbia, IE – Ireland, AO – Angola, CY – Cyprus, UA – Ukraine,
RU – Russian Federation, SK – Slovakia, CG – Congo, KE – Kenya,
BI – Burundi, BR – Brazil, CV – Cape Verde.
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